RORC and osteosarcoma: Beyond immune regulation, accumulating evidence, including our own, has demonstrated that RORγ expression is elevated in multiple aggressive cancers, such as castration-resistant prostate cancer, hepatocellular carcinoma, osteosarcoma, pancreatic cancer, and triple-negative breast cancer, where it functions as an oncogenic driver [23–27].